BIOMARKERS OF HIGH-GRADE SERIOUS OVARIAN CARCINOMAS

摘要

The present disclosure provides biomarkers useful for determining the prognosis of conditions such as ovarian cancer. The presently disclosed subject matter provides angiogenic biomarkers and methods and compositions for predicting overall survival (OS) in women with high-grade serious carcinomas (HGSCs). The presently disclosed subject matter provides compositions and methods that enable rationally directed therapies to improve outcome in women with HGSC.

主权项

1. A method of determining the overall survival of a subject having high-grade serous ovarian cancer (HGSC), comprising:
quantifying an expression level of one or more biomarkers that are associated with overall survival in ovarian cancer in a biological sample derived from a subject relative to a reference control, wherein the biomarker comprises one or more of EPHB2, ERBB2, FLT1, PF4, NRP1, COL4A3, ANGPTL3, ANGPT4, CSF3, CUL7, F2, FOXC2, HGF, HSPG2, ILSRA, ITGB3, LECT1, NOS3, NRP1, PLG, TGFA, TNNI1, AKT1, CD44, F3, GUSB, HIF1A, HPRT1, IL8, JAG1, TEK, and VASH1; and determining one of:
the subject as having a likely shorter overall survival if the expression level of one or more of the biomarkers: EPHB2, ERBB2, FLT1, PF4, NRP1, COL4A3, ANGPTL3, ANGPT4, CSF3, CUL7, F2, FOXC2, HGF, HSPG2, ILSRA, ITGB3, LECT1, NOS3, NRP1, PLG, TGFA, and TNNI1 is higher in the biological sample derived from the subject compared to the reference control orthe subject as having a likely longer overall survival if the expression level of one or more of the biomarkers: AKT1, CD44, F3, GUSB, HIF1A, HPRT1, IL8, JAG1, TEK, and VASH1 is higher in the biological sample derived from the subject compared to the reference control.